chr5-132604806-T-C
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_005732.4(RAD50):āc.2525T>Cā(p.Val842Ala) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.000402 in 1,604,444 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005732.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.2525T>C | p.Val842Ala | missense_variant, splice_region_variant | Exon 16 of 25 | 1 | NM_005732.4 | ENSP00000368100.4 | ||
ENSG00000283782 | ENST00000640655.2 | c.2228T>C | p.Val743Ala | missense_variant, splice_region_variant | Exon 17 of 26 | 5 | ENSP00000491596.2 |
Frequencies
GnomAD3 genomes AF: 0.000191 AC: 29AN: 152218Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000105 AC: 26AN: 248368Hom.: 0 AF XY: 0.0000819 AC XY: 11AN XY: 134234
GnomAD4 exome AF: 0.000424 AC: 616AN: 1452226Hom.: 1 Cov.: 30 AF XY: 0.000415 AC XY: 300AN XY: 722910
GnomAD4 genome AF: 0.000191 AC: 29AN: 152218Hom.: 0 Cov.: 32 AF XY: 0.000188 AC XY: 14AN XY: 74364
ClinVar
Submissions by phenotype
not provided Uncertain:2
The RAD50 c.2525T>C (p.Val842Ala) variant has been reported in the published literature in individuals with advanced cancer (PMID: 28873162 (2017)) and breast cancer (PMID: 16385572 (2006), 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/RAD50)). This variant has also been identified in reportedly healthy individuals (PMID: 29641532 (2018), 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/RAD50)). The frequency of this variant in the general population, 0.00034 (17/50556 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 26787654, 16385572, 33471991, 29641532, 28873162, 26510912, 32212377, 24894818, 19917125) -
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
The p.V842A variant (also known as c.2525T>C) is located in coding exon 16 of the RAD50 gene. The valine at codon 842 is replaced by alanine, an amino acid with similar properties. This change occurs in the first base pair of coding exon 16. This variant has been reported in multiple breast cancer case-control studies (Tommiska J et al. Int. J. Cancer, 2006 Jun;118:2911-6; Damiola F et al. Breast Cancer Res, 2014 Jun;16:R58; Young EL et al. J Med Genet, 2016 06;53:366-76). It has also been reported in 1/1358 non-cancer control individuals and in 0/57 cases, in a study looking at cancer predisposition mutations in patients with cutaneous melanoma and a history of at least two additional non-cutaneous melanoma primary cancers (Pritchard AL et al. PLoS One, 2018 Apr;13:e0194098). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
- -
Nijmegen breakage syndrome-like disorder Uncertain:1
- -
not specified Benign:1
Variant summary: RAD50 c.2525T>C (p.Val842Ala) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00011 in 279768 control chromosomes, predominantly at a frequency of 0.0002 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 3.2 fold of the estimated maximal expected allele frequency for a pathogenic variant in RAD50 causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (6.3e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.2525T>C has been reported in the literature in individuals affected with breast cancer or non-Hodgkin lymphoma (Tommiska_2006, Schuetz_2009, Damiola_2014). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance and likely benign. Based on the evidence outlined above, the variant was classified as likely benign. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at